Biogen Inc

자세한 내용은 Biogen Inc 회사

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

회사 정보

종목 코드 BIIB

회사 이름Biogen Inc

상장일Sep 17, 1991

CEOMr. Christopher A. (Chris) Viehbacher

직원 수7605

유형Ordinary Share

회계 연도 종료Sep 17

주소225 Binney Street

도시CAMBRIDGE

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호02142

전화17814642000

웹사이트https://www.biogen.com/

종목 코드 BIIB

상장일Sep 17, 1991

CEOMr. Christopher A. (Chris) Viehbacher

회사 임원

이름

이름/직위

직위

주식 보유

변동

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Mr. Jesus B. Mantas

Independent Director

8.42K

+39.19%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+76.33%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.43K

-41.22%

Ms. Susan Langer

Independent Director

3.79K

+166.90%

이름

이름/직위

직위

주식 보유

변동

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Spinal Muscular Atrophy-SPINRAZA

563.30M

23.17%

MS product revenues-TYSABRI

381.50M

15.69%

MS product revenues-Fumarate

344.90M

14.19%

MS product revenues-Interferon

226.30M

9.31%

Biosimilar product revenues-BENEPALI

111.30M

4.58%

Other

803.70M

33.06%

지역별USD

이름

수익

비율

Rest of World

972.70M

40.01%

United States

786.80M

32.37%

United states-Revenues from anti-CD20 therapeutic

378.20M

15.56%

Rest of World-Other revenues

293.30M

12.06%

사업별

지역별

사업별USD

이름

수익

비율

Spinal Muscular Atrophy-SPINRAZA

563.30M

23.17%

MS product revenues-TYSABRI

381.50M

15.69%

MS product revenues-Fumarate

344.90M

14.19%

MS product revenues-Interferon

226.30M

9.31%

Biosimilar product revenues-BENEPALI

111.30M

4.58%

Other

803.70M

33.06%

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

11.57%

PRIMECAP Management Company

10.87%

BlackRock Institutional Trust Company, N.A.

5.93%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.19%

Other

63.39%

주주

비율

The Vanguard Group, Inc.

11.57%

PRIMECAP Management Company

10.87%

BlackRock Institutional Trust Company, N.A.

5.93%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.19%

Other

63.39%

주주 유형

주주

비율

Investment Advisor

52.07%

Investment Advisor/Hedge Fund

25.74%

Hedge Fund

6.51%

Research Firm

2.41%

Pension Fund

2.38%

Bank and Trust

1.80%

Sovereign Wealth Fund

1.64%

Individual Investor

0.17%

Family Office

0.09%

Other

7.19%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

2069

136.06M

92.85%

-10.86M

2025Q1

2149

136.82M

93.38%

-11.44M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

2023Q1

2280

132.71M

91.84%

-5.88M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

16.96M

11.57%

+279.20K

+1.67%

Mar 31, 2025

PRIMECAP Management Company

15.94M

10.88%

-102.95K

-0.64%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.70M

5.94%

+106.24K

+1.24%

Mar 31, 2025

State Street Global Advisors (US)

7.40M

5.05%

-1.34K

-0.02%

Mar 31, 2025

Wellington Management Company, LLP

4.67M

3.19%

-258.29K

-5.24%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.85M

2.63%

+151.39K

+4.10%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

3.03M

2.07%

-8.46K

-0.28%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

2.66M

1.82%

-439.50K

-14.18%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

2.33M

1.59%

+246.45K

+11.86%

Dec 31, 2024

Invesco Capital Management LLC

2.01M

1.37%

+124.81K

+6.62%

Mar 31, 2025

131.950USD

Biogen Inc

131.950

개요

회사

금융